The U.S. FDA and pharma manufacturers are progressing in addressing the nationwide shortage of cancer drugs, with the supply of chemotherapy cisplatin nearing pre-shortage levels. Awareness of this shortage has much improved the collection of carboplatin as well. The FDA and pharma manufacturers achieved this progress due to increased production capacity in response to a lack of 15 cancer drugs due to manufacturing and supply chain issues. Besides, the FDA has arranged for an unnamed manufacturer to import cisplatin from a registered facility outside the U.S. and has allowed Chinese and Indian pharma companies to ship cisplatin, carboplatin, and other injectables to the U.S. Further, the FDA has collaborated closely with five generic manufacturers to increase the supply of another cancer drug, methotrexate. Despite challenges from generic drug makers discontinuing products for economic reasons and manufacturing site closures, the FDA and pharma manufacturers are making substantial strides toward resolution.
To read more, click here.
[Source: Fierce Pharma, September 14th, 2023]